Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Waldek

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Inherited Metabolic Disease|March 19, 2014
Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort studyL J Anderson, W Henley, K M Wyatt, et al.
Journal of Inherited Metabolic Disease|June 8, 2014
Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort studyL J Anderson, W Henley, K M Wyatt, et al.
QJM : Monthly Journal of the Association of Physicians|July 28, 2010
Fabry disease: a review of current management strategiesA Mehta, M Beck, F Eyskens, et al.
The New England Journal of Medicine|July 7, 2001
Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's diseaseC M Eng, N Guffon, W R Wilcox, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1994
Complete regression of recurrent diffuse malignant lymphoma after withdrawal of cyclosporin A in a renal transplant recipientP A Kalra, G N Wood, D J O'Donoghue, et al.
Health Technology Assessment (Winchester, England)|October 24, 2012
The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disordersK Wyatt, W Henley, L Anderson, et al.
Molecular Genetics and Metabolism|March 12, 2013
A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effectsR Giugliani, S Waldek, D P Germain, et al.
Journal of Inherited Metabolic Disease|March 10, 2007
Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry RegistryC M Eng, J Fletcher, W R Wilcox, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Inherited Metabolic Disease|March 19, 2014
Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort studyL J Anderson, W Henley, K M Wyatt, et al.
Journal of Inherited Metabolic Disease|June 8, 2014
Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort studyL J Anderson, W Henley, K M Wyatt, et al.
QJM : Monthly Journal of the Association of Physicians|July 28, 2010
Fabry disease: a review of current management strategiesA Mehta, M Beck, F Eyskens, et al.
The New England Journal of Medicine|July 7, 2001
Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's diseaseC M Eng, N Guffon, W R Wilcox, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1994
Complete regression of recurrent diffuse malignant lymphoma after withdrawal of cyclosporin A in a renal transplant recipientP A Kalra, G N Wood, D J O'Donoghue, et al.
Health Technology Assessment (Winchester, England)|October 24, 2012
The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disordersK Wyatt, W Henley, L Anderson, et al.
Molecular Genetics and Metabolism|March 12, 2013
A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effectsR Giugliani, S Waldek, D P Germain, et al.
Journal of Inherited Metabolic Disease|March 10, 2007
Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry RegistryC M Eng, J Fletcher, W R Wilcox, et al.
Pageof 5